NLRP3 and atherosclerosis: Similar to Lin et al., treatment with an NLRP3 inhibitor reduced secretion of IL-1β in TET2-deficient macrophages and ameliorated atherosclerosis or heart failure caused by TET2-depleted myeloid cells [85,86].